EPHA10 and breast cancer: Inter-independent genetic profiles reported that the gene amplification of EPHA10 is between 0.8%-17.2% in breast cancer, and a missense mutation in the RTK domain (TCGA data) in 0.2% (5/482) of BC cases [7–9].